The French pharmaceutical industry association, the SNIP, has been indiscussions with senior government officials and parliamentarians to explore prospects for a new framework drug industry agreement with the Jospin Administration.
The SNIP says the framework needs to cover industrial policy and not only public health and budgetary issues. Initial exchanges have, according to the association, provided evidence of a joint desire for partnership and realization, in changed government-industry relations, that take account of the challenges to the industry resulting from accelerated internationalization and steady therapeutic progress.
The group says it has affirmed the industry's commitment to health care expenditure controls, and its support for a coherent development of the generics market "on a sane regulatory and economic base."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze